UH Cancer Center Clinical Trial Finder

Important Disclaimer: This is not a comprehensive list of open studies at the University of Hawai'i Cancer Center. If you do not see what you are looking for here, please do not hesitate to reach out. Our friendly Clinical Trials Office staff would be more than happy to help.

Filter Options

Study Type

Disease Site The primary site of the cancer, or the place in the body where the cancer first starts.

Location

ALLIANCE-A012103

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

PI: Jami Fukui, MD

ALLIANCE-A022102

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

PI: Jared Acoba, MD

ALLIANCE-A032102

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

PI: Jeffery Berenberg, MD

ALLIANCE-A081801

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

PI: Jeffrey Berenberg, MD

ALLIANCE-A222004

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

PI: Ashley Springer, APRN

CASSEL-2024-2

The Ku Ola Project: Enhancing Health Promotion Among Native Hawaiian Men.

PI: Kevin Cassel, MD

CCTG-PR26

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

PI: Jeffrey Berenberg, MD

EAY191

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

PI: Jeffrey Berenberg, MD

ECOG-ACRIN-EA2192

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

PI: Jared Acoba, MD

ECOG-ACRIN-EA9181

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

PI: Craig Boddy, MD

ECOG-ACRIN-EAQ211

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

PI: Dee Ann Omatsu, APRN

ECOG-ACRIN-EAQ222CD

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

PI: Samir Ambrale, MD & Christa Braun-Inglis, APRN

ECOG-ACRIN-EAY191-N4

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

PI: Michael Carney, MD

ECOG-ACRIN-MM1OA-EA02

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

PI: Craig Boddy, MD

KWEE-2021-1

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

PI: Sandi Kwee, MD

NRG-BN003

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

PI: Richard Lee, MD

NRG-BN013

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

PI: Jared Hara, MD

NRG-BR007

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

PI: Jami Fukui, MD

NRG-BR009

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

PI: Jodi Kagihara, MD

NRG-CC008

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

PI: Jami Fukui, MD

NRG-CC012CD

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

PI: Karen Rowan, APRN

NRG-CC014

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

PI: Jared Hara, MD

NRG-GI008

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

PI: Jared Acoba, MD

NRG-GU010

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

PI: Jared Hara, MD

NRG-GU013

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

PI: Jared Hara, MD

NRG-GY026

Disease Site
The primary site of the cancer, or the place in the body where the cancer first starts.